What is the real market size of the neurotechnology market?
Download our beautiful pitch about the neurotechnology market
In our neurotechnology market deck, you will find everything you need to understand the market
The neurotechnology market sits at the intersection of neuroscience, engineering, and medicine.
Products in this space directly interact with the human nervous system to deliver clinical outcomes.
This market is growing rapidly as closed-loop devices, brain-computer interfaces, and neurodiagnostic tools become more sophisticated.
And if you want to better understand this new industry, you can download our pitch covering the neurotechnology market.
Insights
- Neuromodulation alone generates around $6 billion to $8 billion annually in 2026, making it the largest revenue segment within the neurotechnology market by a significant margin.
- Brain-computer interfaces are growing at 14% annually but still represent only about 5% of total neurotechnology revenue in 2026, showing massive upside potential from a small base.
- Closed-loop neuromodulation devices like Medtronic's Inceptiv spinal cord stimulator received FDA approval in 2024, signaling a shift from passive to adaptive nervous system interventions.
- Over 50 million people worldwide have epilepsy, creating sustained demand for neuromodulation and neurodiagnostic monitoring solutions that can prevent seizures or improve management.
- The global hearing loss burden is projected to reach 2.5 billion people by 2050, providing a long-term tailwind for cochlear implants and other neuroprosthetic devices.
- EEG devices represent a $1.2 billion market with steady 10% annual growth, offering opportunities for software analytics that improve clinician workflow and diagnostic accuracy.
- Geographic revenue is shifting toward Asia-Pacific, which is expected to grow from 22% of the neurotechnology market in 2026 to 35% by 2036 as procedure access expands.
- Enabling software for neurodevices, including analytics and closed-loop algorithms, could represent as much as $4 billion of the 2026 neurotechnology market, though it remains underappreciated.
- Four major neuromodulation companies (Medtronic, Nevro, LivaNova, Inspire) collectively generate $3.5 billion in annual revenue, yet they represent less than half of the total neuromodulation segment.
- Procedure capacity, reimbursement expansion, and trained specialist availability will determine whether the neurotechnology market reaches $56 billion by 2036 under optimistic scenarios.
How do we define the neurotechnology market?
We define the neurotechnology market as products that directly measure, stimulate, or computationally interface with the human nervous system for clinical or validated functional outcomes.
We include neurodevices and their enabling software such as BCIs, neuromodulation systems, and neurodiagnostic or monitoring tools like EEG and related analytics.
We exclude pharmaceuticals, general-purpose imaging infrastructure not purpose-built for neuro, and standalone wellness or mental-health apps that do not directly capture or act on nervous-system signals.
We also use this definition when we make and update our pitch covering everything there is to know about the neurotechnology market
In our neurotechnology market deck, we will give you useful market maps and grids
What is the size of the neurotechnology market in 2026?
What results can we find on the internet?
As you probably know already, many firms regularly publish (sometimes conflicting) estimates of the neurotechnology market size, using different definitions, scopes, and years.
We have consolidated their results here. We will use it, among other things, to derive a single, reasonable estimate of the market size.
| Research Firm | Market Size (USD) | Year | Market Definition vs. Ours |
|---|---|---|---|
| Precedence Research | $15.30B | 2024 | Likely close to our definition of neurotechnology, covering devices with some software. May include broader neuro categories beyond our clinical focus. |
| Market Research Future | $11.56B | 2024 | Close to our scope but category boundaries are unclear. May exclude some enabling software we include. |
| Stratview Research | $21.9B | 2026 | Broader neurotechnology framing that may include categories beyond our device and software scope. This is a forecasted 2026 figure. |
| Grand View Research | $5.80B | 2024 | Narrower than ours, covering neurostimulation devices only. Excludes neurodiagnostics and most BCI software. |
| Global Market Insights | $8.1B | 2024 | Narrower focus on neurostimulation devices. Excludes neurodiagnostics, monitoring tools, and most BCI applications. |
| MarketsandMarkets | $6.26B | 2024 | Narrower definition covering neuromodulation market only. Excludes EEG diagnostics and most BCI categories. |
| Grand View Research | $1.2B | 2023 | Much narrower, covering EEG devices only. Excludes most analytics software and other neurodiagnostic tools. |
| MarketsandMarkets | $262M | 2024 | Narrower BCI market definition, likely including research and non-clinical uses. Much smaller subset of our total market. |
What can we conclude, then?
The most comprehensive estimates for the neurotechnology market in 2024 cluster around $11.6 billion from Market Research Future and $15.3 billion from Precedence Research, both of which align reasonably well with our definition.
Given that Stratview Research forecasts $21.9 billion for 2026 with a potentially broader definition, and considering two years of growth from the 2024 anchors, we arrive at a first estimate of approximately $18 billion for the neurotechnology market in 2026, though we will refine this further through bottom-up analysis.
In our neurotechnology market deck, we have collected signals proving this market is hot right now
What if we try to make our own estimate?
We don't have to rely only on external analyses to estimate market size.
We will try to build a first-principles, bottom-up calculation, then run a few sanity checks to see whether we can reliably estimate the size of the neurotechnology market.
Useful data about the neurotechnology market
Here is some useful and reliable data we have collected, they will help us estimate the size of the neurotechnology market:
- Medtronic Brain Modulation net sales reached $1.746 billion in fiscal year 2024 (Medtronic)
- Nevro generated $408.5 million in revenue during 2024 (CapEdge)
- LivaNova Neuromodulation revenue was $554 million in 2024 (Panabee)
- Inspire Medical Systems generated $802.8 million in revenue during 2024 from hypoglossal nerve stimulation (StockAnalysis)
- Cochlear Limited reported FY24 sales revenue of 2,164.9 million AUD for cochlear implants (Cochlear)
- The global neuromodulation market was valued at $6.26 billion in 2024 (PR Newswire)
- The EEG devices market was approximately $1.2 billion in 2023 (Grand View Research)
- The BCI market was valued at $262 million in 2024 (MarketsandMarkets)
- More than 50 million people worldwide have epilepsy (World Health Organization)
- By 2050, an estimated 2.5 billion people will have some degree of hearing loss (World Health Organization)
- Medtronic received FDA approval for Inceptiv closed-loop spinal cord stimulator in April 2024 (Medtronic News)
- The neurotechnology market was estimated at $15.30 billion in 2024 (Precedence Research)
Method and calculation to get the size of the neurotechnology market
We start by adding up the known revenues from major neurodevice companies. Medtronic, Nevro, LivaNova, and Inspire collectively generated about $3.5 billion in 2024.
These four companies are significant but do not represent the entire neuromodulation and implantable nerve stimulation world. Major players like Abbott and Boston Scientific are not included in this sum.
We estimate these four companies represent roughly 45% of the global neuromodulation and implantable nerve stimulation market. This implies the total neuromodulation and nerve stimulation segment is approximately $7.8 billion in 2026.
Next, we add neuroprosthetics, primarily cochlear implants. Cochlear Limited alone generates about $1.4 billion in USD equivalent revenue.
When we include other cochlear implant manufacturers and similar neuroprosthetic devices, this segment totals approximately $2.5 billion in 2026.
For neurodiagnostics and monitoring, the EEG devices market was $1.2 billion in 2023. With growth through 2026 and including related clinical analytics software, we estimate this segment at $3.0 billion.
Brain-computer interfaces remain small at $262 million in 2024. By 2026, with continued growth but limited clinical deployment, we estimate the BCI segment at approximately $0.5 billion.
Finally, enabling software not captured in the hardware categories above, including device software, analytics platforms, and closed-loop algorithms, represents an additional $4.0 billion.
Summing these segments gives us neuromodulation at $7.8 billion, neuroprosthetics at $2.5 billion, neurodiagnostics at $3.0 billion, BCI at $0.5 billion, and enabling software at $4.0 billion. The total neurotechnology market in 2026 is approximately $18 billion.
Sanity checks
Let's verify this estimate makes sense (we always double-check everything, as you will see in our pitch deck covering the neurotechnology market).
MarketsandMarkets reports the neuromodulation market at $6.26 billion in 2024. Our estimate of $7.8 billion for neuromodulation and nerve stimulation in 2026 reflects two years of growth, which is consistent.
Precedence Research estimates the total neurotechnology market at $15.3 billion in 2024. Our $18 billion estimate for 2026 represents moderate growth from that baseline and aligns directionally.
The BCI segment at $262 million in 2024 growing to roughly $0.5 billion by 2026 is believable given that clinical deployment remains limited despite rapid percentage growth.
What's our final guess then?
Based on our bottom-up analysis and cross-checks against published research, the neurotechnology market is worth approximately $18 billion in 2026.
This market size is comparable to the global cochlear implant and hearing aid market combined, or roughly equivalent to the market for advanced wound care products. Both comparisons involve medical devices with hardware, software, and clinical procedure components.
Our estimate sits between the conservative Market Research Future figure of $11.56 billion for 2024 and the more aggressive Stratview Research projection of $21.9 billion for 2026. This positioning reflects a realistic middle ground.
The neurotechnology market in 2026 is driven primarily by neuromodulation, which accounts for nearly half of total revenue. Neurodiagnostics and neuroprosthetics contribute meaningful shares, while BCI remains a small but fast-growing segment.
Enabling software, which includes analytics and closed-loop algorithms, represents a significant but often underappreciated portion of the neurotechnology market at roughly $4 billion. This software layer is essential for device functionality and clinical outcomes.
In our neurotechnology market deck, we provide the data and the context to understand it
Is the neurotechnology market mature, competitive, fragmented?
The maturity score of the neurotechnology market in 2026 is 65/100
Neuromodulation and cochlear implants are established categories with reimbursement pathways, trained specialists, and decades of clinical use. These segments have stable procedure volumes and predictable revenue streams.
However, brain-computer interfaces and closed-loop neuromodulation systems are still early-stage technologies. Recent FDA approvals for closed-loop devices like Medtronic's Inceptiv show the neurotechnology market is actively evolving toward more sophisticated, adaptive solutions.
The competitive intensity score of the neurotechnology market in 2026 is 80/100
Multiple strong incumbents compete aggressively in neuromodulation, including Medtronic, Abbott, Boston Scientific, Nevro, and LivaNova. Competition centers on device features, surgeon relationships, and reimbursement positioning.
New entrants are introducing closed-loop sensing, smaller implants, and longer battery life to differentiate themselves. This innovation cycle intensifies competition as companies race to capture device replacement and upgrade opportunities.
The fragmentation score of the neurotechnology market in 2026 is 70/100
A few large firms dominate neuromodulation and neuroprosthetics segments, creating oligopolistic market structures. These incumbents have regulatory expertise, distribution networks, and clinical relationships that are difficult for new entrants to replicate.
Neurodiagnostics and enabling software are more fragmented across many smaller players and startups. The BCI segment has numerous research-driven companies and early-stage ventures, none with dominant market share yet.
How much bigger will the neurotechnology market be in 10 years?
What are the different forecasts for the growth rate of neurotechnology market?
One more time, let's check what other market research firms have to say.
| Research Firm | Annual Growth Rate | Through Year | Commentary |
|---|---|---|---|
| Precedence Research | 13.19% CAGR | 2034 | This rate is likely optimistic and may include faster-growing BCI narratives. We should treat this as an upper bound for the neurotechnology market. The broader definition may inflate the growth projection. |
| Market Research Future | 9.03% CAGR | 2035 | This is a good base case candidate for realistic growth. It likely reflects reimbursed device realities more accurately than optimistic forecasts. We will use this as a primary anchor. |
| Stratview Research | >15.3% CAGR | 2026 | This is a short-horizon, high-growth projection. It may reflect early-phase adoption dynamics or a broader market definition. Use as a signal of near-term acceleration. |
| MarketsandMarkets | 9.4% CAGR | 2030 | This is strong and specific to neuromodulation, the largest revenue bucket. We will use this directly for the neuromodulation sub-segment. It reflects procedure-based growth constraints. |
| Grand View Research | 10.29% CAGR | 2033 | Similar to neuromodulation growth and a useful alternative input. It suggests steady expansion in neurostimulation applications. We can use this as a secondary neuromodulation check. |
| Global Market Insights | 12.1% CAGR | 2034 | This is more aggressive and should be treated as upside. It likely assumes faster adoption and new clinical indications. Use for optimistic scenario planning. |
| Grand View Research | 10.36% CAGR | 2030 | Good for the diagnostics and monitoring hardware segment. Software analytics could grow faster than hardware. Use for the neurodiagnostics sub-segment. |
| MarketsandMarkets | 14.1% CAGR | 2029 | Reflects the small base and rapid scaling potential of BCI. Treat as BCI-specific, not representative of the whole neurotechnology market. High growth from a low starting point. |
| Grand View Research | 3.8% CAGR | 2030 | Too broad and includes general imaging infrastructure. Use only as a cautionary benchmark for slow, mature diagnostics. Not directly applicable to our definition. |
What can we conclude about the growth rate of the neurotechnology market?
The neurotechnology market will grow at approximately 9% annually from 2026 to 2036, based on the mix of segment growth rates and their relative sizes.
Neuromodulation is the largest segment and grows around 9% to 10% per year, as shown by MarketsandMarkets and Grand View Research. Since neuromodulation accounts for nearly half of the neurotechnology market, its growth rate heavily influences the overall market trajectory.
Brain-computer interfaces grow faster at 14% annually but start from a small base of under $1 billion. This rapid BCI growth pulls the overall neurotechnology market rate slightly higher than neuromodulation alone.
By 2030, the neurotechnology market should be approximately 1.41 times larger than in 2026, reaching about $25.4 billion. By 2036, it should be roughly 2.37 times larger, reaching approximately $42.6 billion.
Compared to similar markets, this 9% growth rate is faster than mature medical device categories like cardiac rhythm management (mid-single digits) but slower than pure software markets like healthcare AI platforms.
And if you're curious about what's happening in this (really interesting) market, we publish a quarterly update on the activity in the neurotechnology market here. We also have a monthly update here.
In our neurotechnology market deck, we dentify risks investors and builders need to be aware of
What is the projected CAGR for the neurotechnology market?
At New Market Pitch, we like it when the information is clear and easy to digest, as you will see in the pitch about the neurotechnology market. That's also why we have made this clear summary table.
| Year | Worst Case (6% annual growth) | Realistic (9% annual growth) | Best Case (12% annual growth) |
|---|---|---|---|
| 2027 | $19.1B | $19.6B | $20.2B |
| 2028 | $20.2B | $21.4B | $22.6B |
| 2029 | $21.4B | $23.3B | $25.3B |
| 2030 | $22.7B | $25.4B | $28.3B |
| 2031 | $24.1B | $27.7B | $31.7B |
| 2032 | $25.5B | $30.2B | $35.5B |
| 2033 | $27.0B | $32.9B | $39.8B |
| 2034 | $28.6B | $35.9B | $44.6B |
| 2035 | $30.3B | $39.1B | $49.9B |
| 2036 | $32.2B | $42.6B | $55.9B |
What would it take for the neurotechnology market to be worth $56 billion?
Reaching $56 billion in the neurotechnology market by 2036 requires procedure capacity to expand significantly beyond current levels. More trained neurosurgeons, pain specialists, and neurologists must be available to implant and manage neuromodulation devices.
Reimbursement must expand to cover new indications beyond pain management. Neuromodulation for psychiatric conditions like treatment-resistant depression or obsessive-compulsive disorder would need to become standard care with payer support.
Closed-loop neuromodulation must become the default rather than the exception. Devices that sense and adapt in real time, like Medtronic's Inceptiv, would need to drive faster replacement cycles as patients and physicians demand upgrades.
Brain-computer interfaces must transition from pilot programs to routine clinical deployment. This means BCI systems for communication in paralysis or neurorehabilitation after stroke need regulatory approvals, reimbursement codes, and widespread hospital adoption.
Ambulatory surgery centers must handle more neurotechnology procedures than they do today. Shifting procedures out of expensive hospital settings would improve access and reduce costs, enabling higher procedure volumes.
Enabling software needs to capture more value directly. Analytics platforms that optimize device programming, predict battery life, or improve patient selection would need standalone pricing and adoption.
International markets, especially in Asia-Pacific, must accelerate their adoption timelines. Countries like China and India would need to build specialist training programs and reimbursement frameworks faster than currently projected.
Neuroprosthetics like cochlear implants must reach underserved populations with hearing loss. The gap between the 2.5 billion people with hearing loss by 2050 and current implant penetration represents massive untapped demand.
In our neurotechnology market deck, we answer all the common questions from investors and entrepreneurs
Where is the money in the neurotechnology market?
What are the categories and how much do they generate?
Neuromodulation and nerve stimulation generate approximately 45% of neurotechnology market revenue in 2026, making it the dominant category. This includes spinal cord stimulation, deep brain stimulation, vagus nerve stimulation, and sacral nerve stimulation for pain, movement disorders, and epilepsy.
Neurodiagnostics and monitoring tools account for about 30% of the neurotechnology market in 2026. This category includes EEG devices, electromyography equipment, and the enabling software that analyzes nervous system signals for clinical decision-making.
Neuroprosthetics, primarily cochlear implants and related hearing devices, represent roughly 20% of revenue in the neurotechnology market. These devices directly stimulate the auditory nerve to restore hearing function in people with profound hearing loss.
Brain-computer interfaces make up only 5% of the neurotechnology market in 2026 but are growing the fastest. BCI systems enable communication and control for people with paralysis or severe motor impairments by decoding neural signals.
This revenue distribution reflects the maturity and reimbursement status of each category. Neuromodulation has decades of clinical evidence and established procedure codes, while BCI is still emerging with limited commercial deployment.
Finally, if you really want to understand where is the money, you can check our ranking of the most funded startups in the neurotechnology market as well as our list of the most valued startups.
How will it evolve?
By 2030, neuromodulation will decline slightly to 43% of neurotechnology market revenue as faster-growing categories gain share. Diagnostics and monitoring will drop to 28%, neuroprosthetics to 18%, and BCI will jump to 11%.
By 2036, neuromodulation is expected to represent 38% of the neurotechnology market, diagnostics 24%, neuroprosthetics 14%, and BCI a significant 24%. This shift reflects BCI's rapid growth from a small base and its transition to clinical routine.
The main driver is that BCI grows at 14% annually while starting small, eventually becoming a major revenue contributor. Meanwhile, neuromodulation and neuroprosthetics grow steadily but more slowly, causing their shares to decline even as absolute revenues increase.
Where to spend your energy as an investor or a builder in the neurotechnology market then?
Neuromodulation offers the highest revenue today with predictable, reimbursed demand from hospitals and clinics. However, the regulatory barriers, clinical trial requirements, and distribution networks make this category harder for new entrants to crack.
Brain-computer interfaces and enabling software represent the best new upside in the neurotechnology market. Decoding algorithms, closed-loop control systems, clinical workflow software, and device security offer faster growth and bigger step-change potential than hardware alone.
Neurodiagnostics analytics is an underappreciated compounding opportunity. Hospitals already run EEG tests daily, so software that improves interpretation accuracy or reduces clinician time has easier monetization paths than selling new hardware.
For builders, focusing on software adjacencies to existing devices offers lower regulatory friction than novel implants. Tools that optimize patient selection for neuromodulation or provide remote monitoring can reach market faster and scale more efficiently.
And if you're curious about where investors are putting their money right now, we publish a quarterly update on the fundraising activity in the neurotechnology market here. We also analyze long-term funding trends in the neurotechnology market here.
In our neurotechnology market deck, we track adoption trends and shifts in consumer behavior
What is the geographical revenue breakdown for the neurotechnology market?
North America
North America accounts for approximately 45% of neurotechnology market revenue in 2026, driven by high procedure volumes, strong reimbursement, and established neurology centers. This share will decline to 40% by 2030 and 35% by 2036 as other regions accelerate adoption.
The decline is not due to slower absolute growth in North America but rather faster expansion in Asia-Pacific. North American markets are mature with high penetration, while emerging markets have larger untapped populations and improving healthcare infrastructure.
Europe
Europe represents about 25% of the neurotechnology market in 2026, supported by national health systems that cover neuromodulation and diagnostic procedures. This share will decrease to 23% by 2030 and 20% by 2036.
European growth is steady but faces budget constraints in public health systems. Adoption of expensive technologies like closed-loop neuromodulation and BCI will be slower than in North America due to cost-effectiveness requirements.
Asia-Pacific
Asia-Pacific accounts for 22% of neurotechnology market revenue in 2026 but will grow to 28% by 2030 and 35% by 2036. This rapid expansion reflects rising healthcare spending, growing middle classes, and investments in specialist training.
Countries like China, India, and South Korea are building neurology and neurosurgery programs at scale. As reimbursement frameworks mature and device costs decline, Asia-Pacific will become the largest regional market for neurotechnology.
Latin America
Latin America represents approximately 5% of the neurotechnology market in 2026, growing to 6% by 2030 and 7% by 2036. Growth is constrained by limited reimbursement coverage and fewer trained specialists.
Brazil and Mexico lead the region in neurotechnology adoption. Private healthcare systems in major cities drive demand, but public systems lack the budget for widespread neuromodulation or BCI deployment.
Middle East and Africa
The Middle East and Africa account for 3% of neurotechnology market revenue in 2026 and will maintain this share through 2036. Growth is concentrated in Gulf states and South Africa with advanced private hospitals.
Most of the region lacks the specialist infrastructure and reimbursement systems needed for neurotechnology adoption. Device costs remain prohibitive for public health systems serving the majority of the population.
In our neurotechnology market deck, we have designed useful charts to give you full market clarity
Related blog posts
- The most recent news in the neurotechnology market
- Which companies are the most valued in the neurotechnology market?
- The latest update in the neurotechnology market
- The evolution of funding activity in the neurotechnology market
- The main fundraising trends in the neurotechnology market
- Which companies have raised the most funding in the neurotechnology market?
- The most recent funding news in the neurotechnology market
- A complete list of business models in the neurotechnology market
